Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven M Francque

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Obesity (Silver Spring, Md.)|December 17, 2013
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitusH Carlijne Hassing, R Preethi Surendran, Bruno Derudas, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2023
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practiceJeffrey V Lazarus, Laurent Castera, Henry E Mark, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatmentPierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Journal of Hepatology|September 5, 2022
Non-invasive tests for clinically significant portal hypertension after HCV cureGeorg Semmler, Sabela Lens, Elias L Meyer, et al.
Journal of Hepatology|November 28, 2024
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver diseaseJuan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm, et al.
Hepatology (Baltimore, Md.)|August 4, 2023
A global action agenda for turning the tide on fatty liver diseaseJeffrey V Lazarus, Henry E Mark, Alina M Allen, et al.
Journal of Hepatology|June 23, 2023
A global research priority agenda to advance public health responses to fatty liver diseaseJeffrey V Lazarus, Henry E Mark, Alina M Allen, et al.
Hepatology (Baltimore, Md.)|June 26, 2023
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E Rinella, Jeffrey V Lazarus, Vlad Ratziu, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Obesity (Silver Spring, Md.)|December 17, 2013
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitusH Carlijne Hassing, R Preethi Surendran, Bruno Derudas, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2023
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practiceJeffrey V Lazarus, Laurent Castera, Henry E Mark, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatmentPierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Journal of Hepatology|September 5, 2022
Non-invasive tests for clinically significant portal hypertension after HCV cureGeorg Semmler, Sabela Lens, Elias L Meyer, et al.
Journal of Hepatology|November 28, 2024
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver diseaseJuan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm, et al.
Hepatology (Baltimore, Md.)|August 4, 2023
A global action agenda for turning the tide on fatty liver diseaseJeffrey V Lazarus, Henry E Mark, Alina M Allen, et al.
Journal of Hepatology|June 23, 2023
A global research priority agenda to advance public health responses to fatty liver diseaseJeffrey V Lazarus, Henry E Mark, Alina M Allen, et al.
Hepatology (Baltimore, Md.)|June 26, 2023
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E Rinella, Jeffrey V Lazarus, Vlad Ratziu, et al.
Pageof 6